Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81398 | 0.98 | NPC1 (0.59) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| SCHEMBL6435991 | 0.98 | NPC1 (0.59) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| SCHEMBL6436241 | 0.98 | NPC1 (0.59) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| SCHEMBL6431667 | 0.98 | NPC1 (0.59) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| SCHEMBL127819 | 0.95 | — | — | |
| Vinyl Chloride SCHEMBL11146132 | 0.92 | NPC1 (0.53) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| SCHEMBL308515 | 0.90 | — | — | |
| SCHEMBL9624068 | 0.90 | POLB (0.54) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| SCHEMBL22784002 | 0.90 | NPC1 (0.52) | SMN1; SMN2NPC1HTTGAAEPHX1 | |
| Acrylamide SCHEMBL27873607 | 0.90 | NPC1 (0.52) | SMN1; SMN2NPC1HTTGAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023972-A1 | SHALE SWELLING INHIBITORS | ISP INVESTMENTS LLC (US) | 2019-01-24 | — | — | US | claimed |
| EP-2414456-B1 | DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2018-12-26 | — | — | EP | claimed |
| US-10081757-B2 | Shale swelling inhibitors | ISP INVESTMENTS LLC (US) | 2018-09-25 | — | — | US | claimed |
| EP-2346909-B1 | POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF | ISP INVESTMENTS INC (US) | 2018-05-16 | — | — | EP | claimed |
| US-20150344767-A1 | SHALE SWELLING INHIBITORS | ISP INVESTMENTS INC. (US) | 2015-12-03 | — | — | US | claimed |
| US-8895478-B2 | Degradable polymer compositions and uses thereof | ISP INVESTMENTS INC. (US) | 2014-11-25 | — | — | US | claimed |
| WO-2014088850-A2 | SHALE SWELLING INHIBITORS | ISP INVESTMENTS INC. (US) | 2014-06-12 | — | — | WO | claimed |
| US-20120157352-A1 | DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-06-21 | — | — | US | claimed |
| US-20110277844-A1 | POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF | HERCULES LLC | 2011-11-17 | — | — | US | claimed |
| EP-0774096-B1 | A METHOD FOR INHIBITING HYDRATE FORMATION | EXXON PRODUCTION RESEARCH CO (US) | 2000-03-01 | — | — | EP | claimed |
| EP-0774096-A4 | A METHOD FOR INHIBITING HYDRATE FORMATION | EXXON PRODUCTION RESEARCH CO (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0774096-A1 | A METHOD FOR INHIBITING HYDRATE FORMATION | EXXON PRODUCTION RESEARCH COMPANY (US) | 1997-05-21 | — | — | EP | claimed |
| US-5600044-A | USING A WATER SOLUBLE N-ALKYLACRYLAMIDE POLYMER | EXXON PRODUCTION RESEARCH COMPANY (US) | 1997-02-04 | — | — | US | claimed |
| WO-1996008672-A1 | A METHOD FOR INHIBITING HYDRATE FORMATION | EXXON PRODUCTION RESEARCH COMPANY (US) | 1996-03-21 | — | — | WO | claimed |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023156599-A1 | SYNTHESIS OF BRUTON'S TYROSINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-24 | — | — | WO | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| US-4945006-A | UNSATURATED CYCLIC AMIDES, ANAEROBIC PROCESS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| EP-0379305-A1 | Low odor adhesive compositions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| US-3936473-A | COPPER OR NOBLE METAL SALT, OXYGEN AND ORGANIC ACID CATALYST | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | SMN1; SMN2 1765/4885NPC1 4257/4885HTT 2488/4885 |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | LTB4R, LTC4S, LTA4H | SMN1; SMN2 3664/4885NPC1 670/4885HTT 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.